Skip to main content
. Author manuscript; available in PMC: 2013 May 9.
Published in final edited form as: ACS Nano. 2010 Sep 28;4(9):4971–4978. doi: 10.1021/nn100560p

Figure 7.

Figure 7

In vivo antitumor effects of PCNDXR (2.0, 5.0, or 7.5 mg/kg of DXR) administered by intraperitoneal injection to female nude mice bearing MDA-MB-231 mammary tumors (n = 3 mice with bilateral tumors, 6 tumors per group). (A) Mean tumor volume. Pairwise tests were performed to assess statistical significance and were Bonferroni-corrected; * indicates p < 0.05 for PCNDXR doses 5.0 and 7.5 mg DXR/kg compared with PBS (points, raw mean; error bars, standard error). PCNDXR at 2.0 mg DXR/kg dose was also statistically different on days 12 and 15 (not shown in plot). (B) Body weights of mice in each treatment group (points, mean; error bars, standard error).